Current treatment of atypical mycobacteriosis (Q28265322)

Expert Opinion on Pharmacotherapy

Europe PubMed Central

title

Current treatment of atypical mycobacteriosis (English)

0 references

author name string

Jaime Esteban

series ordinal

1

0 references

Alberto Ortiz-Pérez

series ordinal

2

0 references

language of work or name

English

0 references

publication date

December 2009

0 references

published in

0 references

volume

10

0 references

issue

17

0 references

page(s)

2787-99

0 references

cites work

An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium avium intracellulare infection in patients with HIV or AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterial Diseases Other Than Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Therapy of nontuberculous mycobacterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Surgical treatment of pulmonary diseases due to nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Clinical implications of Mycobacterium kansasii species heterogeneity: Swiss National Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Septic arthritis caused by Mycobacterium kansasii in a prosthetic knee joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Rifampin resistance in Mycobacterium kansasii is associated with rpoB mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Activity of clarithromycin alone and in combination in a murine model of Mycobacterium kansasii infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium xenopi clinical relevance and determinants, the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium celatum sp. nov

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium celatum, an emerging pathogen and cause of false positive amplified Mycobacterium tuberculosis direct test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Pneumonia and bacteremia due to Mycobacterium celatum masquerading as Mycobacterium xenopi in patients with AIDS: an underdiagnosed problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Successful treatment of Mycobacterium ulcerans osteomyelitis with minor surgical debridement and prolonged rifampicin and ciprofloxacin therapy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Epidemiology of infections due to nonpigmented rapidly growing mycobacteria diagnosed in an urban area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Activities of linezolid against rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

A comparison between disk diffusion and microdilution for susceptibility testing of Mycobacterium fortuitum complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Detection of lfrA and tap efflux pump genes among clinical isolates of non-pigmented rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Intrinsic macrolide resistance in rapidly growing mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium chelonae necrotizing pneumonia after allogeneic hematopoietic stem cell transplant: report of clinical response to treatment with tigecycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Antibiotic susceptibility pattern of Mycobacterium marinum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Disseminated Mycobacterium lentiflavum infection in a human immunodeficiency virus-infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Human infections due to Mycobacterium lentiflavum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium lentiflavum infection in immunocompetent patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Cervical lymphadenitis caused by Mycobacterium lentiflavum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Agents of newly recognized or infrequently encountered mycobacterial diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363

Mycobacterium haemophilum osteomyelitis: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903369363